Phase III Clinical Development and Regulatory Transition Planning

The contract titled Phase III Clinical Development and Regulatory Transition Planning focuses on strategic guidance for advancing a therapeutic or medical product from Phase II to Phase III clinical trials. It requires a detailed analysis of the regulatory pathway to ensure compliance with current and anticipated requirements from health authorities, as well as development of a long-term roadmap that integrates clinical, manufacturing, and commercialization goals. The work must account for global regulatory harmonization, risk mitigation strategies, and feasibility assessments for large-scale trial design and patient recruitment. This is a subcontract under the Advanced Research Projects Agency for Health, part of the Department of Health and Human Services, with a NAICS code of 541620 indicating management, scientific, and technical consulting services. The opportunity was posted on August 5, 2026, with a response deadline of October 15, 2026. There is no set-aside designation specified, and the place of performance is not defined, allowing flexibility in where the work is conducted. The contract emphasizes expert-level planning to de-risk the transition to pivotal trials and secure regulatory alignment for future approval and market access.